Results 31 to 40 of about 55,225 (233)

Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients. [PDF]

, 2014
BackgroundGender-based differences in disease onset in murine models of malignant peripheral nerve sheath tumor (MPNST) and in patients with Neurofibromatosis type-1-(NF-1)-associated or spontaneous MPNST has not been well studied.MethodsForty-three ...
Dry, Sarah M, Eilber, Fritz C, Federman, Noah, Li, Yunfeng, Nakashima, Jonathan, Shurell, Elizabeth, Smith, Kathleen B, Tam, Brenna M, Tap, William D, Tran, Linh M, Wu, Hong   +10 more
core   +2 more sources

Neurofibromatosis type 1

, 2015
Neurofibromatosis type 1 (NF1), previously known as von Recklinghausen disease, is a neurogenetic disorder distinct from neurofibromatosis type 2 (NF2). Approximately 1:2500 to 1:3500 individuals worldwide are affected, regardless of ethnicity or race.
Jacqueline L, Anderson, David H, Gutmann
  +5 more sources

Children with 5′-end NF1 gene mutations are more likely to have glioma [PDF]

, 2017
Objective:To ascertain the relationship between the germline NF1 gene mutation and glioma development in patients with neurofibromatosis type 1 (NF1).Methods:The relationship between the type and location of the germline NF1 mutation and the presence of ...
Anastasaki, Corina, Gao, Feng, Gutmann, David H, Morris, Stephanie M   +3 more
core   +2 more sources

Plexiform neurofibromatosis type 1

Indian Journal of Medical Research, 2016
A 16 yr old boy presented to the department of Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India, in 2013 with primary cosmetic concern about swelling in the left upper limb which was progressively increasing over the last few years.
Sharma, Surendra K., Sharma, Abhishek
openaire   +2 more sources

MRI Analysis of Neurofibromatosis Type 1

Pediatric Neurology Briefs, 1998
Serial MRI scans of 30 patients (mean age, 12 years) with neurofibromatosis Type 1 (NF-1) showed the evolution of high-signal brain lesions in a prospective study at the University of Connecticut Health Center, Farmington, and Children’s Medical Center ...
J Gordon Millichap
doaj   +1 more source

Lisch Nodules in Neurofibromatosis Type 1

Pediatric Neurology Briefs, 1991
The prevalence of Lisch nodules among 167 patients with neurofibromatosis 1 is reported from the Department of Pediatrics, Genetics Division, Miami Children’s Hospital, Miama, FL.
J Gordon Millichap
doaj   +1 more source

The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. [PDF]

, 2017
Low-grade gliomas are one of the most common brain tumors in children, where they frequently form within the optic pathway (optic pathway gliomas; OPGs).
Castillon, Guillaume A, Cimino, Patrick J, Ellisman, Mark H, Gianino, Scott M, Gutmann, David H, Lee, Da Yong, Ma, Yu, Pan, Yuan, Solga, Anne C, Toonen, Joseph A   +9 more
core   +3 more sources

Metabolic Alterations in Macrophage Subtypes Propel Immune and Stromal Remodeling in Neurofibroma's Malignant Progression

MedComm
Neurofibromatosis type 1 (NF1) is characterized by the development of benign plexiform neurofibromas (PNFs). In 10%–15% of patients, these tumors undergo malignant transformation into aggressive malignant peripheral nerve sheath tumors (MPNSTs).
Ling‐Ling Ge, Yue‐Hua Li, Xuan Yu, Ming‐Yan Xing, Yi‐Hui Gu, Wei Wang, Jing‐Xuan Huang, Jun Liu, Hai‐Bing Zhang, Cheng‐Jiang Wei, Zhi‐Chao Wang, Qing‐Feng Li   +11 more
doaj   +1 more source

Learning Disabilities in Neurofibromatosis Type 1

Pediatric Neurology Briefs, 2006
The frequency of specific leaning disabilities (SLD) in neurofibromatosis type 1 (NF1) was determined in a cohort of 81 patients (43 males, 38 females; mean age 11 years 6 months; age range 8-16) followed at Children's Hospital, Westmead, NSW, Australia.
J Gordon Millichap
doaj   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source